Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex Pharma | Vienna | Salute | Ricerca medica e biotecnologica | 111,58 Mrd € | -216,2x | 2,21 | 434,10 € | -2,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Regeneron Pharma | Vienna | Salute | Ricerca medica e biotecnologica | 68,42 Mrd € | 16,1x | 1,68 | 637,60 € | -2,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
argenx SE | Vienna | Salute | Ricerca medica e biotecnologica | 37,78 Mrd € | -951,1x | -11,75 | 614,60 € | -1,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
IQVIA Holdings | Vienna | Salute | Ricerca medica e biotecnologica | 33,52 Mrd € | 26,2x | 9,73 | 190,30 € | -2,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
BioNTech SE DRC | Vienna | Salute | Ricerca medica e biotecnologica | 25,86 Mrd € | -55,8x | 0,5 | 109,60 € | -1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Genmab AS | Vienna | Salute | Ricerca medica e biotecnologica | 11,68 Mrd € | 18,7x | 1,3 | 183,10 € | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Moderna | Vienna | Salute | Ricerca medica e biotecnologica | 11,27 Mrd € | -5,2x | -0,16 | 29,28 € | -3,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Qiagen | Vienna | Salute | Ricerca medica e biotecnologica | 8,15 Mrd € | 103,9x | -1,41 | 38,38 € | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Galapagos NV | Vienna | Salute | Ricerca medica e biotecnologica | 1,52 Mrd € | 7,3x | -0,1 | 22,36 € | -0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Evotec | Vienna | Salute | Ricerca medica e biotecnologica | 1,50 Mrd € | -8,8x | 0,11 | 8,30 € | -2,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Novavax | Vienna | Salute | Ricerca medica e biotecnologica | 1,22 Mrd € | -4x | -0,07 | 7,60 € | -3,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
CureVac NV | Vienna | Salute | Ricerca medica e biotecnologica | 786,55 Mln € | -2,8x | -0,18 | 3,48 € | -0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Valneva | Vienna | Salute | Ricerca medica e biotecnologica | 638,11 Mln € | -72,6x | -0,73 | 3,77 € | 2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Medigene | Vienna | Salute | Ricerca medica e biotecnologica | 22,14 Mln € | -1,2x | -0,03 | 1,55 € | 1,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |